RBC keeps USD 187.00 target for Neurocrine Biosciences stock
Published on 10/15/2026 at 19:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and reporting date
- RBC Capital analyst Brian Abrahams set a USD 187.00 target on October 13, 2026.
- Neurocrine Biosciences will release third-quarter results on November 2, 2026.
- Neurocrine Biosciences stock costs EUR 122.23 at Lang & Schwarz on October 15, 2026 at 7:45 p.m. CEST, up 0.93 percent on Nasdaq from the October 14, 2026 close.
- Neurocrine Biosciences had a USD 13.9 billion market capitalization and a 20.12 price-earnings ratio on October 15, 2026.
RBC Capital kept a Buy rating on Neurocrine Biosciences and set a USD 187.00 price target on October 13, 2026. According to Markets Insider, the target stood 36.29 percent above the USD 137.18 Nasdaq price. At Lang & Schwarz, the stock was trading at EUR 122.23 on October 15, 2026 at 7:45 p.m. CEST; Nasdaq trading was up 0.93 percent from the October 14, 2026 close.
November 2 results date
Neurocrine Biosciences will release its third-quarter 2026 financial results on November 2, 2026, with the conference call scheduled for 1:30 p.m. Pacific Time. The company set the release for 1:00 p.m. Pacific Time. The date and schedule appear in the company announcement carried on its investor-relations page, Neurocrine Biosciences.
Second-quarter revenue rose 39.50 percent
Neurocrine reported USD 959.0 million in revenue for the second quarter of 2026, compared with USD 687.5 million a year earlier. Net profit reached USD 144.4 million, up from USD 107.5 million in the comparable quarter, according to Markets Insider. The 2026 second-quarter net margin was 15.00 percent.
Price range and valuation
The Nasdaq price stood at USD 137.18 on October 15, 2026, inside a USD 122.14 to USD 186.12 52-week range. It was 26.29 percent below the yearly high and 12.32 percent above the yearly low. The session range was USD 135.55 to USD 138.18, while volume reached 583,781 shares against an average of 1,308,107.
Neurocrine Biosciences had a USD 13.9 billion market capitalization and a 20.12 price-earnings ratio on October 15, 2026. The Nasdaq listing gives the stock a direct US trading reference, while the euro quotation provides the German investor view.
Comparison with peers on October 15, 2026
Neurocrine Biosciences: plus 0.93 percent, P/E 20.12, market capitalization USD 13.9 billion
BioMarin Pharmaceutical (Nasdaq, USD): plus 2.76 percent, P/E 145.23, market capitalization USD 11.0 billion
Vertex Pharmaceuticals (Nasdaq, USD): plus 2.39 percent, P/E 29.71, market capitalization USD 129.4 billion
Euro quote after the Xetra close
The Nasdaq price was up 0.93 percent during the October 15, 2026 session, while the Lang & Schwarz quotation placed the stock at EUR 122.23 later in Berlin trading. The next scheduled corporate date is November 2, 2026, when Neurocrine will publish its third-quarter results.
The further course of trading is shown by the continuously updated real-time quote of Neurocrine Biosciences stock.
Neurocrine Biosciences market data
- Company: Neurocrine Biosciences, Inc.
- ISIN: US64125C1099
- Ticker: NBIX
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 15, 2026, 7:45 p.m. CEST): EUR 122.23
- Change on Nasdaq versus October 14, 2026 close: plus 0.93 percent
- Market capitalization: USD 13.9 billion (as of October 15, 2026)
- 52-week range: USD 122.14-186.12 (as of October 15, 2026)
- Sector / Industry: Healthcare / Biotechnology
Market context: Market report Nasdaq Composite.
